乳癌の予測遺伝子検査：企業と競争環境...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
3 Competitive Assessment 9
3.1 Overview 9
3.1.1 BRACAnalysis 10
3.1.2 BreastNext 18
3.1.3 BreastCancer 24
3.1.4 PreventionGenetics CHEK2/BARD1 Sequencing 26
3.1.5 NewGene NGS BRCA1/2 29
3.1.6 TDL BRCA1/2 Full Screening 31
3.1.7 Centogene Breast Ovarian Cancer NGS Panel 33
3.1.8 Mamma GeneProfile 36
3.1.9 23AndMe DNA Spit Kit 38
3.1.10 DeCodeMe Complete Scan 44
3.1.11 Health Compass 46
4 Pipeline Products 48
4.1 Predictive Breast Cancer Gene Tests in Development 48
4.1.1 Myriad Genetics RAD51C Breast Cancer Gene Test 49
4.1.2 23AndMe Exome 80X 50
4.2 Breast Cancer Gene Expression Tests 50
4.2.1 BreastGeneDX 51
4.2.2 Diagnostic Test – Breast Cancer (Queens University/Almac Diagnostics) 52
4.2.3 Diagnostic Test – Breast Cancer (NanoIVD) 53
4.2.4 EpiSwitch OBD27 54
4.2.5 Myriad HRD Test 55
4.2.6 PAM50 Breast Cancer Test 56
4.3 Emerging Sequencing Technology 57
4.4 New Gene Discovery 57
5 Current and Future Players 58
5.1 Overview 58
5.2 Trends in Corporate Strategy 59
5.3 Common Strengths, Weaknesses, Opportunities and Threats 60
5.3.1 Growing Incidence of Breast Cancer 60
5.3.2 Growing Market Opportunities in Emerging Markets 61
5.3.3 Uncertain R&D Outcomes 62
5.3.4 Stringent Government Regulations 62
5.4 Company Profiles 63
5.4.1 Myriad Genetics 63
5.4.2 Ambry Genetics 74
5.4.3 Complete Genomics 78
5.4.4 Navigenics (now Life Technologies) 83
5.4.5 PreventionGenetics 87
5.4.6 Lab21 Ltd. 89
5.4.7 NewGene Ltd. 93
5.4.8 The Doctors Laboratory Ltd. 96
5.4.9 Bioscientia GmBH 99
5.4.10 Centogene AG (Centogene Rostock GmBH) 101
5.4.11 Sistemas Genomicos 103
5.4.12 Grupo Fleury 106
5.4.13 Diagnosticos da America SA (DASA) 109
5.4.14 ATS GeneTech 112
5.4.15 23AndMe 116
5.4.16 BGI-Shenzhen 125
5.4.17 Illumina 129
5.4.18 Life Technologies 137
5.4.19 Roche 143
6 Appendix 147
6.1 Bibliography 147
6.2 Abbreviations 162
6.3 Research Methodology 164
6.3.1 Overview 164
6.3.2 Coverage 164
6.3.3 Secondary Research 165
6.3.4 Forecast Methodology 165
6.4 Physicians and Specialists Included in this Study 167
6.5 Primary Research 168
6.6 Physician Survey 168
6.7 About the Authors 169
6.7.1 Analysts 169
6.7.2 Global Head of Healthcare 170
6.8 Definitions 171
6.9 About MediPoint 172
6.10 About GlobalData 172
6.11 Contact Us 172
6.12 Disclaimer 173